middle.news
Race Oncology Safely Advances RC220-Doxorubicin Combo in Solid Tumour Trial
9:07am on Thursday 19th of June, 2025 AEST
•
Healthcare
Read Story
Race Oncology Safely Advances RC220-Doxorubicin Combo in Solid Tumour Trial
9:07am on Thursday 19th of June, 2025 AEST
Key Points
First patient safely dosed with RC220 plus doxorubicin at lead Australian site
No treatment-related dose-limiting adverse effects observed
Phase 1 trial underway across Australia, Hong Kong, and South Korea
Trial uses Bayesian design to accelerate dose and safety assessments
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE